This is a mechanism module, not a specific disease. It models the tumor-SUPPRESSIVE mechanism of senescence/aging and is the complement of the deleterious `cellular_senescence` module; the two share the senescence-arrest concept but diverge downstream (barrier to transformation here vs. SASP/accumulation/dysfunction there). IMPORTANT framing: this module does NOT assert that aging is net-protective against cancer - older people have higher overall cancer incidence. It captures specific, conserved tumor-suppressive mechanisms (oncogene-induced/replicative senescence arrest; aging-associated loss of stemness) that operate as independent barriers, strongest cell-intrinsically. The age/stemness arm is not a senescence readout and should be reused only when direct evidence shows that loss of stemness in the aged cell of origin reduces tumorigenic capacity, not for generic aging or stem-cell depletion. Disease nodes representing loss of senescence, escape from senescence, or decreased senescence are inverse mechanisms and should not directly conform to the positive arrest or barrier nodes; model an evidenced positive barrier and its bypass separately. The terminal barrier covers both prevention of malignant transformation and restraint of progression from a benign or low-grade state. For the positive senescence branch, conformance requires evidence of a stable or essentially irreversible senescence-associated proliferative arrest in an at-risk or premalignant cell population and an evidence-linked tumor-suppressive consequence such as reduced clonal expansion, malignant transformation, or progression. Expression of p16/p21 or SA-beta-gal alone, quiescence, differentiation, and reversible pharmacologic cytostasis are insufficient. Disease-specific or population-level epidemiologic claims (e.g. the age-contextualized accelerated-aging/early-onset-cancer association) belong on the relevant disorder or comorbidity/trajectory entry, not here. The age/stemness arm is anchored on PMID:39633048 (Zhuang et al., Nature 2025); the senescence-barrier arm on the classic tumor-suppressive senescence literature.
Oncogenic and Replicative Stress in Cells at Risk
trigger
Cells at risk of malignant transformation sustain pro-senescent stresses: activated oncogenes (oncogene-induced senescence), telomere attrition from repeated division (replicative senescence), and severe or irreparable DNA damage (genotoxic stress). Rather than tolerating these lesions, cells capable of division can route them into the senescence program.
Downstream
-
Senescence-Associated Tumor-Suppressive Arrest
Senescence-Associated Tumor-Suppressive Arrest
central effector
The p16INK4a/Rb and p53/p21 tumor-suppressor pathways impose an essentially permanent cell-cycle arrest. By halting the proliferation of damaged or oncogene-expressing cells, this arrest is the cell-intrinsic core of senescence's tumor-suppressive function - the same arrest that, in a different (chronic, SASP-driven) context, becomes deleterious in the `cellular_senescence` module.
Downstream
-
Barrier to Malignant Transformation
Aging-Associated Loss of Stemness
modifier
A convergent, later-life thread: aging degrades the fitness and stemness of the stem/progenitor cells of origin, reducing their capacity to initiate tumors. This is mechanistically distinct from the senescence arrest (it reflects stem-cell decline rather than p16/p53 arrest) but converges on the same tumor-suppressive outcome and supplies the age-context for this module.
Downstream
-
Barrier to Malignant Transformation